These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 20802306

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P, Graff J, Olsson AG, Pedersen TJ, Jönsson B, IDEAL Trial Investigators.
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS.
    Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
    Araujo DV, Ribeiro de Souza CP, Bahia LR, Rey HC, Dos Santos Junior B, Tura BR, Berwanger O, Buehler AM, Silva MT.
    Value Health; 2011 Jan; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
    Montouchet C, Ruff L, Balu S.
    J Med Econ; 2013 Jul; 16(7):907-16. PubMed ID: 23641809
    [Abstract] [Full Text] [Related]

  • 10. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M, O'Donnell JC, Jones P.
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM, Penning-van Beest FJ, Plat AW, Meerding WJ, Webb K, Sturkenboom MC, Herings RM.
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated.
    Jacobson TA, Wertz DA, Hoy T, Kuznik A, Grochulski D, Cziraky M.
    Mayo Clin Proc; 2008 Dec; 83(12):1316-25. PubMed ID: 19046550
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin.
    Jacobson TA, Wertz DA, Kuznik A, Cziraky M.
    Curr Med Res Opin; 2013 Jul; 29(7):773-81. PubMed ID: 23647370
    [Abstract] [Full Text] [Related]

  • 17. A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets.
    Lachaine J, Merikle E, Tarride JE, Montpetit M, Rinfret S.
    Clin Ther; 2007 Mar; 29(3):519-28. PubMed ID: 17577472
    [Abstract] [Full Text] [Related]

  • 18. A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in hypertensive patients without prior cardiovascular disease.
    Foody JM, Joyce AT, Jeffers BW, Liu LZ, Benner JS.
    Am J Ther; 2011 Mar; 18(2):110-6. PubMed ID: 20216383
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective.
    Straka RJ, Mamdani M, Damen J, Kuntze CE, Liu LZ, Botteman MF, Koren MJ.
    Curr Med Res Opin; 2007 Jul; 23(7):1517-29. PubMed ID: 17535539
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.